Efficacy and safety of One-day transdermal fentanyl switching from immediately-release oxycodone in advanced breast cancer patients.
- Conditions
- Breast Cancer
- Registration Number
- JPRN-UMIN000007830
- Lead Sponsor
- Saitama Breast Cancer Clinical Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Not provided
Oxnorm Contraindications 1)Severe respiratory depression, severe COPD 2)During acute attack of bronchial asthma 3)Secondary cardiac failure of chronic pulmonary diseases 4)During convulsive state 5)Paralytic ileus 6)Hypersensitivity to a group of opium alkaloids 7)Hemorrhagic colitis 8)Bacterial diarrhea OneDuro Patch Contraindication 1)hypersensitivity to any of the ingredients of the product Careful Administration 2)Respiratory dysfunctions such as chronic lung diseases 3)Asthma 4)Severe bradyarrhythmia 5)Severe hepatic or renal dysfunction 6)Organic brain disorders such as intracranial hypertension, disturbed consciousness, coma or brain cancer 7)Skin diseases such as atopic dermatitis ieczema on adhesive site 8)40dgree or more fever 9)History of drug dependence 10)Pregnancy, nursing women 11)Within next 2 days before using Fentanyl patch, antagonists of opioid receptor such as Pentazocine or Buprenorphine etc. are administered or planned to administer 12)below the age of 20 13)Attending doctors judgement
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patient satisfaction at day 14 and day 28
- Secondary Outcome Measures
Name Time Method Physician satisfaction at day 28 Pain degree at day 14 and day 28 4-level evaluation of Nausea, Vommiting, constipation, daytime drowsiness at day 14 and day 28